| scholarly article | Q13442814 |
| P2093 | author name string | Vito Guerra | |
| Anna Maria Valentini | |||
| Maria Lucia Caruso | |||
| Federica Di Pinto | |||
| Raffaele Armentano | |||
| Sergio Coletta | |||
| P2860 | cites work | Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 |
| PD-L1 is an independent prognostic predictor in gastric cancer of Western patients | Q27853364 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Immune checkpoint blockade: a common denominator approach to cancer therapy | Q28083981 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy | Q29617774 | ||
| The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification | Q29618627 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients | Q33688662 | ||
| The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints | Q34943776 | ||
| The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy | Q34970884 | ||
| Classifying Cancers Based on T-cell Infiltration and PD-L1. | Q35674821 | ||
| RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues | Q35917676 | ||
| Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors | Q36261635 | ||
| Targeted therapies in gastric cancer and future perspectives. | Q36471685 | ||
| Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. | Q36939402 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| Gastric cancer pathology and underlying molecular mechanisms | Q38122579 | ||
| Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. | Q38204955 | ||
| Update on Epstein-Barr virus and gastric cancer (review). | Q38336778 | ||
| Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. | Q38610333 | ||
| PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. | Q38630412 | ||
| Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer | Q38642012 | ||
| PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer | Q38858292 | ||
| Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway | Q38996832 | ||
| ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer | Q39077848 | ||
| Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing | Q39096557 | ||
| HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. | Q39106714 | ||
| Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials | Q39215902 | ||
| The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors | Q39828989 | ||
| Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients | Q40581214 | ||
| Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma | Q40682693 | ||
| Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration | Q40814909 | ||
| A protein and mRNA expression-based classification of gastric cancer | Q40824215 | ||
| Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas | Q40971062 | ||
| Targeted therapies for gastric cancer: failures and hopes from clinical trials | Q41340207 | ||
| Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection | Q41547569 | ||
| Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers | Q41708934 | ||
| Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas | Q41809459 | ||
| Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. | Q41924371 | ||
| PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer | Q41926342 | ||
| Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry | Q42376660 | ||
| Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma | Q45054030 | ||
| Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. | Q45851280 | ||
| Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer | Q47137632 | ||
| Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. | Q47728785 | ||
| Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. | Q47802088 | ||
| PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics | Q49494082 | ||
| Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients. | Q52649601 | ||
| Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. | Q53837214 | ||
| PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. | Q54935837 | ||
| Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. | Q55307728 | ||
| Clinical Importance of Epstein⁻Barr Virus-Associated Gastric Cancer. | Q55515323 | ||
| IL-18 Induces PD-1-Dependent Immunosuppression in Cancer | Q57556330 | ||
| New monoclonal antibodies against B-cell antigens: Possible new strategies for diagnosis of primary cutaneous B-cell lymphomas | Q58482097 | ||
| Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies | Q58795231 | ||
| Histologic grading of gastric cancer | Q70410675 | ||
| PD-1: an inhibitory immunoreceptor involved in peripheral tolerance | Q73807451 | ||
| Tissue processing and hematoxylin and eosin staining | Q87387123 | ||
| Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer | Q90360938 | ||
| FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 | Q91011455 | ||
| P433 | issue | 2 | |
| P921 | main subject | DNA mismatch repair | Q2984243 |
| P304 | page(s) | 1775-1785 | |
| P577 | publication date | 2019-06-21 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status | |
| P478 | volume | 18 |
Search more.